RhoVac AB participates in Nordic Life Science Days and at Aktiedagen
RhoVac AB ("RhoVac") will, as a natural step in the company’s international communication, participate in Nordic Life Science Days in Malmö, Sweden in September 2017. The company will also present at Aktiedagen in Gothenburg, Sweden later the same month.
RhoVac, a biotechnology company in clinical development, continues the increased international focus and participates in Nordic Life Science Days in Malmö, Sweden on 13-14 September 2017. Nordic Life Science Days is the Nordic region's largest partner conference for the life science industry. Since its inception in 2013, the event has created a place for industry stakeholders to meet.
In addition, high-quality presenters provide insight into the latest trends in science and industry. Nordic Life Science Days attracts leading decision makers from biotechnology, pharma and med tech as well as finance, research, policy and supervisory authorities. The event gives RhoVac the opportunity to present the company and its cancer vaccine RV001 for a number of international pharmaceutical companies and other potential investors at individual meetings. RhoVac will participate with three representatives at this event.
In addition, RhoVac announces that CEO Anders Ljungqvist will present the company, status regarding development projects and the company's plans for 2017/2018 at Aktiedagen in Gothenburg, September 25, 2017, at 14.30 CET. Aktiedagen is held at Svenska Mässan , room H1, Mässans Gata 24, Gothenburg, Sweden.
For more information, please contact:
Anders Ljungqvist – VD, RhoVac AB
Phone: +45 4083 2365
About RhoVac AB
RhoVac AB conducts research and development of immunotherapeutic drugs. The company's main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac's first drug candidate has completed pre-clinical phase and clinical phase I / II study has started spring 2017. RhoVac has its head office at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on AktieTorget, Sweden, a Multilateral Trading Facility (MTF), since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com